# Human Anti-D (rh) Immunoglobulin (Rhesoglobin) Efficacy, Safety and Some Pharmacokinetics Parameters in Pregnant Women

> **NCT05245734** · PHASE4 · UNKNOWN · sponsor: **Biopharma Plasma LLC** · enrollment: 281 (estimated)

## Conditions studied

- Pregnancy Related

## Interventions

- **DRUG:** Human Anti-D (rh) immunoglobulin

## Key facts

- **NCT ID:** NCT05245734
- **Lead sponsor:** Biopharma Plasma LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-02-08
- **Primary completion:** 2025-02
- **Final completion:** 2025-04
- **Target enrollment:** 281 (ESTIMATED)
- **Last updated:** 2024-04-18

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05245734

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05245734, "Human Anti-D (rh) Immunoglobulin (Rhesoglobin) Efficacy, Safety and Some Pharmacokinetics Parameters in Pregnant Women". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05245734. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*